Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 17, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 17, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 599 Common Stock at $493.22 ($295,436) on September 17, 2026; holds 333,344 after (Indirect).
- Open-market sale: disposed of 1,750 Common Stock at $494.34 ($865,096) on September 17, 2026; holds 331,594 after (Indirect).
- Open-market sale: disposed of 1,905 Common Stock at $495.11 ($943,183) on September 17, 2026; holds 329,689 after (Indirect).
- Open-market sale: disposed of 2,182 Common Stock at $496.21 ($1,082,721) on September 17, 2026; holds 327,507 after (Indirect).
- Open-market sale: disposed of 1,953 Common Stock at $497.17 ($970,978) on September 17, 2026; holds 325,554 after (Indirect).
- Open-market sale: disposed of 151 Common Stock at $497.79 ($75,166) on September 17, 2026; holds 325,403 after (Indirect).
- Open-market sale: disposed of 332 Common Stock at $499.10 ($165,701) on September 17, 2026; holds 325,071 after (Indirect).
- Open-market sale: disposed of 468 Common Stock at $500.09 ($234,043) on September 17, 2026; holds 324,603 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $501.60 ($80,256) on September 17, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 17, 2026; holds 413,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,712,580 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-17 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-09-17 | Open-market sale | Common Stock | 599 | $493 | $295.4K | 333,344 |
| 2026-09-17 | Open-market sale | Common Stock | 1,750 | $494 | $865.1K | 331,594 |
| 2026-09-17 | Open-market sale | Common Stock | 1,905 | $495 | $943.2K | 329,689 |
| 2026-09-17 | Open-market sale | Common Stock | 2,182 | $496 | $1.1M | 327,507 |
| 2026-09-17 | Open-market sale | Common Stock | 1,953 | $497 | $971.0K | 325,554 |
| 2026-09-17 | Open-market sale | Common Stock | 151 | $498 | $75.2K | 325,403 |
| 2026-09-17 | Open-market sale | Common Stock | 332 | $499 | $165.7K | 325,071 |
| 2026-09-17 | Open-market sale | Common Stock | 468 | $500 | $234.0K | 324,603 |
| 2026-09-17 | Open-market sale | Common Stock | 160 | $502 | $80.3K | 324,443 |
| 2026-09-17 | Option exercise/conversion | Stock Option | 9,500 | — | — | 413,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-17 | Option exercise/conversion (9,500 shares) |
| 2026-09-17 | Open-market sale (599 shares) |
| 2026-09-17 | Open-market sale (1,750 shares) |
| 2026-09-17 | Open-market sale (1,905 shares) |
| 2026-09-17 | Open-market sale (2,182 shares) |
| 2026-09-17 | Open-market sale (1,953 shares) |
| 2026-09-17 | Open-market sale (151 shares) |
| 2026-09-17 | Open-market sale (332 shares) |
| 2026-09-17 | Open-market sale (468 shares) |
| 2026-09-17 | Open-market sale (160 shares) |
| 2026-09-17 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.